Remember that weight can fluctuate due to factors like water retention, so dont be discouraged by minor changes
Sarcopenia and the effects of obesity and diabetes
All of the five therapeutic GLP-1RAs, currently approved for therapy of type 2 diabetes, are peptide molecules, which are administered in subcutaneous injections
The program theoretically will expire at the end of 2027, although those taking GLP-1 drugs for obesity at that point are likely to advocate for its continuation
Similar to medications for chronic conditions, like asthma, diabetes or high blood pressure, GLP-1 medications only work for those who continue to take them
Perhaps its most famous role, GLP-1 crosses the blood-brain barrier to act directly on appetite centres in the brain, enhancing feelings of fullness and reducing hunger signals